Skip to content
Screener

Roivant Sciences ROIV Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
$00.0%
Revvity logo
RevvityRVTY
$10.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0.010.0%
Moderna logo
ModernaMRNA
AbbVie logo
AbbVieABBV
CNT
Canton Strategic HoldingsCNTN

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$26.25B+244%
Enterprise value$26.28B+244%
P/S3,485×+3,157×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemJune 30, 2026March 31, 2026
Total liabilities384,624416,275
Commitments and contingencies (Note 10)
Shareholders’ equity:
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 722,668,062 and 720,352,386 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively
Additional paid-in capital5,130,9265,024,826
Accumulated deficit(900,354)(501,814)
Accumulated other comprehensive income7014,358
Shareholders’ equity attributable to Roivant Sciences Ltd.4,231,2734,527,370

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's common stock, par value (in dollars per share)?
Roivant Sciences (ROIV) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Roivant Sciences's common stock, par value (in dollars per share) changed year-over-year?
Roivant Sciences's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Roivant Sciences's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Roivant Sciences's common stock, par value (in dollars per share) has grown at a 2.6% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Roivant Sciences's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude